Deonikar P, Kavdia M. Low micromolar intravascular cell-free hemoglobin concentration affects vascular NO bioavailability in sickle cell disease: a computational analysis. J Appl Physiol 112: 1383-1392, 2012. First published January 5, 2012 doi:10.1152/japplphysiol.01173.2011.-In sickle cell disease, the changes in RBC morphology destabilize the red blood cell (RBC) membrane and lead to hemolysis. Several experimental and clinical studies have associated intravascular hemolysis with pulmonary hypertension in sickle cell disease. Cell-free hemoglobin (Hb) from intravascular hemolysis has high affinity for nitrixc oxide (NO) and can affect the NO bioavailability in the sickle cell disease, which may eventually lead to pulmonary hypertension. To study the effects of intravascular hemolysis related cell-free Hb concentrations on NO bioavailability, we developed a two-dimensional mathematical model of NO biotransport in 50-m arteriole under steady-state sickle cell disease conditions. We analyzed the effects of flowdependent NO production and axial and radial transport of NO, a recently reported much lower NO-RBC reaction rate constant, and cell-free layer thickness on NO biotransport. Our results show that the presence of cell-free Hb concentrations as low as 0.5 M results in an approximately three-to sevenfold reduction in the predicted smooth muscle cell NO concentrations compared with those under physiological conditions. In addition, increasing the diffusional resistance for NO in vascular lumen from cell-free layer or reducing NO-RBC reaction rate did not improve the NO bioavailability at the smooth muscle cell layer significantly for cell-free Hb concentrations Ն1 M. These results suggest that lower NO bioavailability due to low micromolar cell-free Hb can disturb NO homeostasis and cause insufficient bioavailability at the smooth muscle cell layer. Our results supports the hypothesis that hemolysis-associated reduction in NO bioavailability may play a role in the development of pathophysiological complications like pulmonary hypertension in sickle cell disease that are observed in several clinical and experimental studies. Several studies (25, 34) have indicated a strong association between intravascular hemolysis in sickle cell disease and manifestation of pulmonary hypertension, priapism, leg ulceration, acute chest pain, and increased morbidity in sickle cell patients. Clinical studies (9, 54, 70) have reported that 20 -30% sickle cell disease patients show increase in pulmonary hypertension. Additionally, sickle cell disease patients with pulmonary hypertension have a higher morbidity rate than patients without pulmonary hypertension (70). A postmortem histopathological analysis showed evidence of pulmonary hypertension in all sickle cell patients (28).
nitric oxide; red blood cells; microcirculation; mathematical model SICKLE CELL DISEASE IS A HEREDITARY hemolytic disorder caused by a single nucleotide polymorphism in the ␤-globin gene that leads to substitution of glutamic acid by valine on the ␤-chain of hemoglobin (Hb; Ref. 68 ). The resulting Hb, known as sickle cell Hb, undergoes polymerization with nearby globin chains (69) under deoxygenated conditions. Because of its lower solubility, polymerized sickle cell Hb aggregates in the red blood cells (RBCs; Ref. 19 ) thereby increasing the RBC rigidity (69) . This change in RBC morphology destabilizes the RBC membrane and leads to intravascular hemolysis (60) .
Several studies (25, 34) have indicated a strong association between intravascular hemolysis in sickle cell disease and manifestation of pulmonary hypertension, priapism, leg ulceration, acute chest pain, and increased morbidity in sickle cell patients. Clinical studies (9, 54, 70) have reported that 20 -30% sickle cell disease patients show increase in pulmonary hypertension. Additionally, sickle cell disease patients with pulmonary hypertension have a higher morbidity rate than patients without pulmonary hypertension (70) . A postmortem histopathological analysis showed evidence of pulmonary hypertension in all sickle cell patients (28) .
The manifestation of sickle cell disease complications such as pulmonary hypertension has been attributed to the loss of nitric oxide (NO) bioavailability (60) . The endothelium-derived NO plays a key role in the regulation of vascular smooth muscle tone (1, 31, 53) . NO production from endothelium and its consumption by soluble guanylate cyclase (sGC) in smooth muscle cells and RBC-Hb in vascular lumen are important parameters for NO homeostasis in vasculature. Hb has a very high affinity for NO (k Hb-NO ϭ ϳ10 7 M Ϫ1 ·s Ϫ1 ) (18, 20) . However, NO is preserved from being completely scavenged by RBC-Hb by mechanisms that include diffusional resistances in the vascular lumen (46, 48) and the RBC membrane barrier (27) for NO. A small amount of cell-free Hb is observed in hemolytic disorders including thalassemia and sickle cell disease (35, 54, 60) . These small amounts of cell-free Hb may affect the NO bioavailability in the sickle cell disease (35, 60) and may lead to hypertensive effects (17, 58) .
Intravascular hemolysis can affect NO bioavailability in three ways. First, arginase, which is released from RBCs as a result of hemolysis, competes with endothelial nitric oxide synthase (eNOS) for arginine (a substrate for eNOS-based NO production). A reduction in arginine reduces NO production from endothelium and consequently NO bioavailability (30, 54) . Second, increased levels of asymmetric dimethyl arginine, an eNOS inhibitor, reduce the NO production in sickle cell disease (34, 44, 64) . Third, cell-free Hb released from hemolysis scavenges NO, leading to lower NO bioavailability. Cell-free Hb consumes NO very efficiently to form methemoglobin and nitrate in oxygenated conditions and nitrosyl Hb in deoxygenated conditions (8, 20) . Injections of cell-free Hb caused severe vasoconstriction leading to hypertensive effects in animal models (17, 58) . Although cell-free Hb resulting from hemolysis is targeted for removal by endocytosis via its binding to haptoglobin, recurring hemolysis under disease conditions like sickle cell disease can lead to depletion of haptoglobin and increase the cell-free Hb concentrations (63) .
The role of low cell-free Hb in sickle cell disease on NO bioavailability and development of pulmonary hypertension is controversial (5, 24) . In a recent review, Bunn et al. (5) questioned the role of loss of NO bioavailability due to cell-free Hb from hemolysis in the development of pulmonary hypertension in sickle cell patients. They reported that factors like left ventricular failure, high cardiac output, and vascular inflammation and occlusion may be responsible for pulmonary hypertension in sickle cell disease. On the other hand, several clinical studies have shown a strong association between increased hemolysis and loss of NO bioavailability in hemolytic diseases including sickle cell disease (33) , paroxysmal nocturnal hemoglobinuria (29) , and malaria (76) . The severity of hemolysis is also associated with complications such as pulmonary hypertension, priapism, and leg ulceration (2, 13, 25, 49, 52, 65, 74) . Using computational modeling approach, Jeffers et al. (32) studied the effects of cell-free Hb on NO bioavailability under hemolytic anemias. Their results showed that 1 M cell-free intravascular Hb can significantly reduce NO bioavailability in smooth muscle layer. In addition, infusion of gaseous NO and NO donors mitigated vasoconstriction caused by intravascular hemolysis (51) , indicating the role of cell-free Hb in lowering NO bioavailability.
To understand the effect of low cell-free Hb concentrations on NO bioavailability in the microcirculation, we developed a two-dimensional computational model of NO biotransport in the presence of intravascular cell-free Hb. Simulations were performed under steady-state sickle cell disease and compared with normal physiology. To better reflect the steady-state sickle cell disease hemodynamics in microcirculation, the model incorporates several novel features that include the flow-dependent NO production and axial and radial transport of NO, a recently reported much lower NO-RBC reaction rate constant (16) , and different cell-free layer thickness near the vascular wall. We estimated the effect of blood velocity, cell-free layer thickness, and NO uptake rate by RBCs on overall NO bioavailability at the endothelium and smooth muscle cell layer in the presence of small amounts of cellfree Hb.
MATHEMATICAL MODELING
Model geometry. A two-dimensional model was developed in cylindrical geometry to NO biotransport in an arteriole with 50-m inner diameter and 500-m length as shown in Fig. 1A . The model geometry was described in detail in Deonikar and Kavdia (14) . Briefly, the model geometry consisted of concentric cylindrical components representing cell-rich lumen, cell-free zone, endothelium, interstitial space, smooth muscle cell layer, nonperfused tissue, and perfused parenchymal tissue regions. NO produced from endothelium diffuses to luminal and abluminal regions and is metabolized in different arteriolar regions. Governing equations. Steady-state NO transport and its interactions in the arteriole can be described by the following equation.
where D NO is the NO diffusivity, CNO is NO concentration, RNO is NO consumption reaction rates, and qNO is NO production rate. NO consumption reactions in different regions of the arteriole are listed in Table 1 . NO is consumed by oxygen, RBC-bound Hb, and cell-free Hb in the vascular lumen. In the cell-free layer, NO is consumed by oxygen and cell-free Hb. NO autoxidation reaction accounts for NO consumption in the endothelial, interstitial, and nonperfused tissue region. In the smooth muscle cell region, NO is consumed by oxygen and soluble guanylate cyclase. NO production from arteriolar endothelium is dependent on shear stress and in turn the blood velocity. Estimation of arteriolar and capillary endothelium NO production is discussed in detail in Deonikar and
Kavdia (14) . Average velocity of blood, v z, is equal to ͑1 Ϫ r 2 ր R 2 ͒ϫvzmax, where vzmax is the maximum velocity of blood at the center of the arteriole of radius R. Boundary conditions. Zero flux boundary conditions are applied at the center of the arteriole and at the outer surface of perfused tissue. Continuity of NO flux and NO concentration was applied at all other interfaces except endothelial interfaces. The boundary condition at the endothelium-cell-free zone interface was:
ͯEndot helium ϭ P NO (2) and at the endothelium-interstitial space interface was:
where P NO is the NO release rate from endothelium. Model parameters. Model parameters pertaining to the geometry are listed in Table 2 . The diameter of the 500-m long arteriolar segment studied was 50 m. The endothelium layer and interstitial space thickness were 0.5 m each (40, 75) . Smooth muscle cell layer thickness was 6 m (26) and that of nonperfused tissue region was 30 m (38). To understand the effect of the cell-free layer on NO bioavailability, simulations were performed for of cell-free layer thicknesses of 0, 0.5, 1, 2, 3, 4, 4.5, and 6 m.
Hemodynamic parameters reflecting physiological and steadystate sickle cell disease conditions are listed in Table 3 . For simulations performed under physiological conditions, we used hematocrit (Hct) of 45% and average blood velocity of 0.5 cm/s (23, 39, 57, 59, 73) . Under steady-state sickle cell disease conditions, we used Hct of 25% (3, 32) and average blood velocity of 0.2 cm/s (12). Blood velocities for large arteries were found to be elevated in children with sickle cell disease (56) . However, several human and animal studies (21, 22, 61) have reported abnormalities in the blood velocities in microvessels. Lipowsky et al. (47) reported that the exposure to circulating sickle cells increases vascular resistance fourfold and results in a degradation of microvascular function. In a transgenic sickle cell mouse model specifically developed to study these abnormalities in the microvessels, Embury el al. (21) reported a ϳ2.5-fold reduction in the mean RBC velocity under sickle cell conditions compared with the physiological conditions.
For this study, RBC encapsulated Hb concentrations were 9.135 nM for 45% Hct and 5.075 mM for 25% Hct based on 20.3-mM Hb concentrations in a single RBC. Intravascular cell-free Hb concentrations of 0, 0.5, 1, and 4 M were used to study the effect of low micromolar cell-free Hb concentrations in the vascular lumen on NO bioavailability. All of the Hb concentrations used were per heme basis.
The reaction rate constant for NO autooxidation reaction was 9.6 ϫ 10 6 M Ϫ2 ·s Ϫ1 (45) . We (16) (73) . The mixing cup concentration of NO is the velocity-weighted average NO concentration exiting the vessel segment and represents the concentration of NO exiting this blood vessel. This can also represent amount of NO being transported from upstream to downstream locations in a vessel. Mixing cup concentrations were calculated using the following equation:
where C NO_end represents the predicted NO concentrations at the end of the arteriole.
Numerical methods. Equation 1 was solved numerically with appropriate boundary conditions to obtain NO concentration profiles using FlexPDE5 software (PDESolutions, Antioch, CA). Adoptive mesh finite element algorithm used in this software allows mesh generation in proportion to the concentration gradients in respective regions. The relative accuracy used in this study was 0.005 for all simulations. Figure 1B shows the arteriolar lumen NO concentration distribution at the steady state for sickle cell . However, the mixing cup NO concentrations were similar for cell-free Hb concentration of 4 M for both reaction rate constants. The mixing cup NO concentration was higher at the blood velocity of 0.5 cm/s than that at 0.2 cm/s for both NO-RBC reaction rate constants at a given cell-free Hb concentration.
RESULTS

Cell-free hb as low as 0.5 m affects NO transport in the vascular lumen.
disease conditions for cell-free Hb concentrations of 0, 0.5, 1, and 4 M. The Hct and blood velocity were 25% (3, 32) and 0.2 cm/s (12), respectively. the NO concentration in the arteriolar lumen decreased with increase in cell-free Hb for both NO-RBC reaction rate constants. The highest predicted NO concentrations were observed when cell-free Hb was 0 M and the lowest for cell-free Hb of 4 M. The reduction in predicted NO concentrations was ϳ15 nM (at k NO-RBC ϭ 0.2 ϫ 10 5 M Ϫ1 ·s Ϫ1 ; blood velocity ϭ 0.5 cm/s) for a change in cell-free Hb from 1 to 4 M. The reduction in predicted NO concentrations was ϳ220 nM for a change in cell-free Hb from 0 to 1 M. Thus the reduction in predicted NO concentration was ϳ15 times higher for 0 to 1 M compared with that of for 1 to 4 M. For cell-free Hb concen-
Effect of cell-free Hb on steady-state NO concentration
profile across the arteriole under physiological and sickle cell disease conditions. Steady-state NO concentration profiles at the end of the arteriolar segment across all the arteriolar regions were estimated for physiological and sickle cell disease conditions and are plotted as a function of distance from the vessel center. The steady-state NO concentration profiles are shown in Fig. 4, A and B , for physiological conditions (Hct ϭ 45% and blood velocity ϭ 0.5 cm/s); in Fig. 4 , C and D, for sickle cell disease conditions (Hct ϭ 25% and blood velocity ϭ 0.2 cm/s); and in Fig. 4 , E and F, for sickle cell disease conditions with higher velocity (Hct ϭ 25% and blood velocity ϭ 0.5 cm/s). The presence of cell-free Hb reduced NO bioavailability across the arteriolar cross section under physiological as well as sickle cell disease conditions as shown in Fig. 4 . At physiological conditions, the NO bioavailability was higher than that at sickle cell disease conditions in the presence of cell-free Hb. Increasing the blood velocity from 0.2 to 0.5 cm/s under sickle cell conditions increased the NO bioavailability in the presence of cell-free Hb; however, it was still lesser than that at physiological conditions.
For physiological conditions (Hct ϭ 45% and blood velocity ϭ 0.5 cm/s), sickle cell disease conditions (Hct ϭ 25% and blood velocity ϭ 0.2 cm/s) and sickle cell disease conditions with higher velocity (Hct ϭ 25% and blood velocity ϭ 0.5 cm/s), Fig. 5 shows steady-state predicted NO concentrations as a function of cell-free Hb concentration at endothelium (Fig. 5, A, C , and E, respectively) and smooth muscle cell layer (Figs. 5, B, D, and F, respectively) . Under sickle cell disease conditions, the predicted endothelium NO concentrations dropped ϳ3-to 13-fold at the endothelium and 3-to 18-fold at the smooth muscle cell layer in the presence of cell-free Hb concentrations of 0.5 to 4 M, compared with those under physiological conditions. The increase in blood velocity from 0.2 to 0.5 cm/s under sickle cell disease conditions increased both endothelial and smooth muscle cell layer steady-state predicted NO concentrations by ϳ2.5 fold; however, they were ϳ1.2-to 7.5-fold lower than those found under physiological conditions. Note that most of the NO concentration drops occur for cell-free Hb concentrations Ͻ1 M. the NO-RBC reaction rate constant of 1.4 or 0.2 ϫ 10 5 M Ϫ1 ·s
Ϫ1
had a negligible effect on predicted endothelial and smooth muscle cell NO concentrations for cell-free Hb concentrations Ͼ1 M. Effect of cell-free zone on NO bioavailability at endothelium and smooth muscle cell layer in the presence and absence of cell-free Hb. The RBC-free layer near the vessel wall acts as one of the important diffusional resistances for NO uptake by RBCs and improves NO bioavailability in vasculature. Because of hemolysis, cell-free Hb can be present in this layer in sickle cell patients. We systematically studied the effect of cell-free layer thickness on predicted NO concentrations at endothelium and smooth muscle cell layer under physiological and sickle cell disease. As seen in Fig. 6 , an increase in cell-free thickness from 0 to 6 m resulted in a lower increase in the predicted endothelial and smooth muscle cell steady-state NO concentrations under sickle cell disease conditions than that observed under physiological conditions. The NO concentration increased up to a 2-m cell-free layer thickness for sickle cell conditions, whereas for normal physiologic con- ditions there was a linear increase in NO concentration from 0.5-to 6-m cell-free layer thickness. In addition, the predicted endothelium and smooth muscle cell NO concentrations were independent of the NO-RBC reaction rate constant for the cell-free Hb concentration of 4 M.
DISCUSSION
In this investigation, a computational analysis of NO bioavailability in microcirculation under sickle cell disease conditions is presented. The mathematical model is used to analyze flow dependent NO production, axial and radial transport of NO, a recently reported much lower NO-RBC reaction rate constant (16) , and different cell-free layer thickness in sickle cell disease conditions.
In sickle cell disease, low amounts of cell-free Hb can significantly reduce NO bioavailability in the vascular lumen. Hb has a high affinity for NO (k Hb-NO ϳ10 7 M Ϫ1 ·s Ϫ1 ; Refs. 8, 18, 20) . The administration of Hb-based oxygen carriers and injection of cell-free Hb produced vasoconstriction in animal models as well as humans (40, 62, 72) . Several experimental and theoretical analyses (29, 32, 33, 76) have demonstrated lower NO bioavailability as a consequence of the presence of cell-free Hb under pathophysiological conditions exhibiting intravascular hemolysis. Approximately 4 M cell-free Hb are reported to be present from intravascular hemolysis under sickle cell disease conditions (60) . Experimental studies have shown that ϳ6 M cell-free Hb considerably reduced NO-induced vasodilation (58, 60) . Our simulations predicted that even lower amounts of cellfree Hb (0.5 and 1 M) can affect NO bioavailability in microcirculation under sickle cell disease conditions. Increasing cell-free Hb concentrations to 4 M further reduced the predicted NO concentrations in the vascular lumen and can affect vasodilation, which is consistent with the previously mentioned experimental studies. Although not considered in this study, the extravasation of cell-free Hb into the vessel wall may occur. The extravasation of a small amount of cell-free Hb in the vessel wall can further lower the overall NO availability as shown by Jeffers et al. (32) and Kavdia et al. (40) .
Sufficient NO bioavailability at the smooth muscle cell is necessary for maintaining the vascular tone (1, 31, 53) . One of the critical factors determining NO bioavailability at the smooth muscle cell layer is NO consumption in the vascular lumen by RBC-Hb (6, 14, 43) . RBCs have been shown to react at a much lower reaction rate with NO than free Hb (7, 16). Using an integrated experimental and computational technique, we (15, 16) recently reported a much lower NO-RBC reaction rate constant of 0.2 ϫ 10 5 M Ϫ1 ·s Ϫ1 than the commonly used NO-RBC reaction rate constant of 1.4 ϫ 10 5 M Ϫ1 ·s Ϫ1 in earlier computational models (4, 7, 11, 36, 37, 42) . A lower NO-RBC reaction rate constant would lead to higher NO bioavailability in vascular lumen as observed in our results. However, NO bioavailability did not change significantly with NO-RBC reaction rates at cell-free Hb concentrations Ն1 M. This indicates that the consumption of NO by cell-free Hb is a critical factor for NO bioavailability and NO-RBCs reaction rate will have little effect on the conclusion of this study. We (14) recently reported that under suitable conditions like lower NO-RBC reaction rate and higher blood velocities, downstream transport of NO is possible. In this investigation, we found no axial gradient of the predicted NO concentrations in the vascular lumen even at a velocity of 0.5 cm/s irrespective of the NO-RBC reaction rate constant value indicating lack of downstream transport of NO.
Predicted endothelium and smooth muscle cell NO concentrations in physiological and sickle cell disease conditions. A reduction in Hct entails an increase in NO bioavailability (16) since less NO is consumed in the vascular lumen. However, our results showed that under sickle cell disease conditions in the presence of cell-free Hb for Hct of 25%, NO levels across the arteriole cross section were much lower than those obtained for physiological Hct of 45%. Of particular importance are the predicted NO concentrations at the endothelial and smooth muscle cell layer, which represent NO bioavailability for sGC activation/vasodilation (1, 31, 53) . Our simulations estimated the smooth muscle cell NO concentrations under physiological conditions to be in the range of ϳ100 to 300 nM, which are within the range of experimentally reported smooth muscle cell concentrations (reviewed in Ref. 10 ).
Jeffers et al. (32) showed that in the presence of 4 M cell-free Hb, the predicted smooth muscle cell NO concentrations decreased from ϳ500 to 140 nM (ϳ3-fold decrease) in a blood vessel of 100-m size in sickle cell disease conditions. With the use of a computational approach that is substantially different from that of Jeffers et al. (32) , our study supports that the hemolysis results in the reduction in NO bioavailability and can disturb NO homeostasis in microcirculation and cause insufficient bioavailability at the smooth muscle cell layer. Our results show that even in the presence of cell-free Hb concentrations as low as 0.5 M, the smooth muscle cell concentrations dropped approximately three-to sevenfold lower compared with those under physiological conditions. Another interesting observation from our results was that for cell-free Hb concentrations of Ն1 M, the predicted endothelium and smooth muscle cell NO concentrations remained similar for different NO-RBC reaction rate constants. This lower NO bioavailability may play a role in the development of pathophysiological complications like pulmonary hypertension observed in several clinical and experimental studies (25, 28, 34, 60, 70) .
Is the cell-free layer an effective diffusional resistance for NO transport in vascular lumen under sickle cell disease conditions? The cell-free layer, formed as a result of aggregation of flowing RBCs towards the center of vessel due to the velocity gradient, offers a significant resistance for NO transport in the vascular lumen and is one of the factors responsible for reduced NO uptake by RBCs (46, 55, 66) . Cell-free layer thickness is dependent on the diameter of the blood vessel (41, 67) and Hct (77) . In addition, changes in cell-free layer thickness can influence NO bioavailability and therefore the blood pressure regulation. Under sickle cell disease conditions, Hct is reported to be ϳ25% (3, 32) , which is much lower than the physiological Hct of 45%. Lowering Hct has been reported to increase the NO bioavailability (16) as a direct consequence of increased cell-free layer thickness. However, we predicted that the increase in the predicted NO concentrations with respect to cell-free layer thickness in the presence of cell-free Hb under sickle cell disease conditions was much lower than that observed under physiological conditions. In addition, the predicted NO concentrations remained similar beyond cell-free layer thickness of 2 m. Thus we conclude that the protective effect offered by the cell-free layer for NO bioavailability in vasculature becomes negligible even in the presence of small amounts of cell-free Hb.
In conclusion, our results indicate that cell-free Hb as low as 0.5 M can significantly lower the NO bioavailability under sickle cell disease conditions. In the presence of cell-free Hb Ն1 M, the predicted NO concentrations in the microcirculation are independent of studied NO-RBCs reaction rates. The protective effects provided by the cell-free layer are compromised due to the presence of cell-free Hb in vascular lumen. The clinical and in vivo evidence from previous studies discussed above linking hemolysis with pulmonary hypertension and our results indicating the significant reduction in NO bioavailability in the presence of cell-free Hb further corroborate the role of hemolysis associated low NO bioavailability in the multifactorial pathogenesis of pulmonary hypertension observed in hemolytic disorders.
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